JPMorgan analyst Anupam Rama lowered the firm’s price target on Neurocrine (NBIX) to $176 from $177 and keeps an Overweight rating on the shares. The firm views the post-earnings weakness in shares of Neurocrine as overdone. It sees an attractive buying opportunity at current share levels. JPMorgan sees upside into the $145-$155 share range driven by Ingrezza and Crenessity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine Biosciences Earnings Call Highlights Growth Momentum
- Neurocrine price target lowered to $177 from $180 at RBC Capital
- Neurocrine price target lowered to $185 from $187 at Needham
- Neurocrine price target lowered to $190 from $195 at BofA
- Neurocrine price target raised to $151 from $149 at Wedbush